Bombay HC in favor of Natco’s Compulsory License

Recently, Bombay High Court supported the Granted compulsory license to Indian pharma company Natco for the sale of a generic version of Bayer’s anti-cancer drug Nexavar. With this decision, Natco will now be legally able to manufacture and sell the generic copy of sorafenib tosylate, a patented kidney cancer drug invented by German Pharma giant…

NATCO Pharma Wins Patent War against Teva Pharmaceuticals.

Hyderabad based-Natco Pharma has won a patent battle against Israeli drug giant Teva Pharmaceuticals, over Copaxone, a drug used to treat multiple sclerosis. Natco markets Copaxone (Glatiramer Acetate) used in the treatment of relapsing-remitting multiple sclerosis — in the US market. The drug’s patent to Teva is set to expire in May. Teva appealed The…

US and India sparring over IPR and trade practices

US and India have been sparring over IPR and trade practices. To begin with US claimed that India’s IPR regime discriminated against U.S. companies, especially in the pharmaceuticals sector, and had expressed concerns over issuing a compulsory license (CL), to Hyderabad-based Natco Pharma to manufacture and produce cancer drug Nexavar at a price 30 times…